PHAR, in collaboration with Novartis, published findings from a modified Delphi panel summarizing expert clinical consensus on managing infusion-related reactions (IRRs) in patients with sickle cell disease (SCD) who are treated with crizanlizumab. IRR management in patients with SCD is dependent on key patient characteristics including: prior history of IRRs to other monoclonal antibodies or medications, changes to crizanlizumab infusion rate and patient monitoring, pain severity relative to patient’s typical SCD crises, and severe allergic symptoms. The full manuscript detailing the methods and findings are published in Annals of Hematology, or can be found on the PHAR publications page.
Archives for 2024
PHAR Conducts Expert Panel on Management of Pharmacodynamic Breakthrough Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria
PHAR, in collaboration with Novartis, published findings from a modified Delphi panel summarizing expert clinical consensus on how to classify and manage pharmacodynamic breakthrough hemolysis (BTH) in patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with complement inhibitors. The paper presents the group’s agreed-upon recommendations on how to manage BTH caused by a complement-amplifying condition, as well as provides a severity classification system for BTH and strategies to mitigate risk of BTH in special circumstances (e.g., vaccination, planned or unplanned surgery, and pregnancy). In general, as severity of BTH increased, experts agreed more interventions to manage the BTH were appropriate. The full manuscript detailing the methods and findings are published in Hematology, or can be found on the PHAR Publications page.